Related Experiment Videos
Lymphocyte migration and multiple sclerosis: relation with disease course and therapy.
A Prat1, A Al-Asmi, P Duquette
1Montreal Neurological Institute, McGill University, Quebec, Canada.
Annals of Neurology
|August 12, 1999
Summary
Lymphocyte migration to the central nervous system is increased in multiple sclerosis patients. Treatments like interferon-beta1b and glatiramer acetate reduce this migration, with interferon-beta1b acting directly on lymphocytes.
Area of Science:
- Neuroimmunology
- Cellular Biology
Background:
- Lymphocyte migration into the central nervous system (CNS) is critical for lesion development in multiple sclerosis (MS).
- Understanding factors influencing this migration is key to developing effective MS therapies.
Purpose of the Study:
- To quantify ex vivo lymphocyte migration rates in patients with different forms of multiple sclerosis.
- To investigate the impact of glatiramer acetate and interferon-beta1b on lymphocyte migration.
Main Methods:
- Fibronectin-coated membrane Boyden chamber assay used to measure lymphocyte migration rates.
- Comparison of migration rates between healthy donors and MS patients (relapsing-remitting, secondary progressive).
- Assessment of in vitro effects of glatiramer acetate and interferon-beta1b on lymphocyte migration.
Main Results:
- Lymphocyte migration rates were elevated in MS patients compared to healthy controls.
- Glatiramer acetate and interferon-beta1b treatments significantly reduced lymphocyte migration in relapsing-remitting MS patients.
- Interferon-beta1b directly inhibited lymphocyte migration in vitro, while glatiramer acetate's effects were indirect.
Conclusions:
- Lymphocyte migration is a key cellular event in multiple sclerosis pathogenesis.
- Both glatiramer acetate and interferon-beta1b demonstrate therapeutic potential by reducing lymphocyte migration.
- Interferon-beta1b exerts a direct effect on lymphocyte migration, whereas glatiramer acetate's mechanism is indirect.